PETALUMA, Calif., April 26, 2006 (PRIMEZONE) -- Dow Pharmaceutical Sciences Inc., which provides product development, clinical research and management services for the biotech and pharmaceutical industries announced today that a new bovine in vitro ocular permeation model has been developed by a team led by Dr. Daniel Bucks, Director of Dow's Drug Transport laboratory. Dr. Bucks will introduce this new drug testing model at a poster presentation at the 2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4 in Fort Lauderdale, Florida.
A Promising In Vitro Drug Testing Model Using Newborn Bovine Eyes
Currently, rabbit or adult bovine eyes are most commonly used for ocular drug penetration studies. Rabbit eyes are appropriate for corneal investigation but are not large enough for scleral testing. Adult bovine eyes are of adequate size for scleral testing but the corneas tend to be damaged.
Dr. Buck's work demonstrates that newborn bovine eyes are of sufficient size for both scleral and corneal testing of drug permeation using the Bronaugh flow-through diffusion cell system. In addition, they are of a higher quality than adult bovine eyes. Lastly, drug permeation is significantly higher in newborn bovine cornea versus rabbit cornea. Thus the newborn bovine eye is a promising model to characterize ocular drug permeation, allowing measurement of both corneal and scleral drug permeation in the same species.
To preview the model in more detail, download a copy of the poster presentation at:
http://www.dowpharm.com/presentation-bovine-r1.asp
Expanded Possibilities in Ophthalmic Product Development
Dr Bucks' Conference Availability
On the Bovine Corneal/Scleral Permeation Model:
http://www.dowpharm.com/presentation-bovine-r1.asp
On Dow Pharmaceutical Sciences, Inc.: www.dowpharmsci.com
Steven R. Smith, Vice President, Marketing & Business Development
707-665-4672
1330 Redwood Way, Petaluma, CA 94954